Neuroscience & Biobehavioral Reviews
December 16, 2025
Rivka Vollebregt, A. J. Storm, Paul J. Lucassen et al.
3 citations
Classical psychedelics, like lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and psilocybin, can alter perception, emotion, and cognition, and have shown promise as 're-purposed' treatments for some psychiatric disorders. Recent trials have, e.g., demonstrated rapid and sustained symptom relief in treatment-resistant depression. While promising as a treatment, the...
Journal of Psychoactive Drugs
November 9, 2025
James M Zech, Jérémie Richard, Grant Jones
Psychedelic-assisted interventions are emerging as potential treatments for substance use disorders, including alcohol use disorder (AUD). While recent randomized controlled trials suggest efficacy for certain psychedelics and related compounds in treating AUD, the impact of naturalistic psychedelic use on problematic alcohol consumption remains underexplored. This study examines associations...
Psychopharmacology
October 27, 2025
David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al.
Psychedelic treatments are considered to involve unique treatment challenges relative to other psychiatric interventions, though these are typically not explored in detail within clinical trial reports. To determine the types of challenges that providers encounter while administering psychedelic drugs in research settings and to assess provider opinions on safeguards that may be pursued to...
C&EN Global Enterprise
October 20, 2025
Special To C En Mara Johnson-Groh
In a suburb of Vancouver, Canada, a nondescript three-story building sits alongside a strip of parking lots. From the outside, it looks like an ordinary commercial office space. But inside is something more extraordinary: rows of shelves stacked with plastic tubs full of magic mushrooms—mushrooms that contain the hallucinogenic chemical psilocybin. In a year, enough psychedelic mushrooms can be...
Clinical Chemistry
October 1, 2025
Stephanie Marco
Abstract Background Psychedelic and dissociative drugs, including psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), and ketamine, have garnered significant interest for their therapeutic potential in treating various mental health disorders. However, their psychoactive properties pose substantial risks when used in contexts requiring unimpaired cognitive...
Brazilian Journal of Science
September 29, 2025
Pinelopi Vlotinou, Konstantinos Christodoulou, Anna Tsiakiri et al.
Classical psychedelics encompass psilocybin, lysergic acid diethylamide (LSD), N, N-dimethyltryptamine (DMT), and mescaline and are psychoactive substances that primarily function as agonists at the serotonin 5-hydroxytryptamine receptors (5-HT). In the immediate term, they modify perception, cognition, emotional state, social processing, and introspection, leading to a subjective mystical...
International Journal of Molecular Sciences
September 14, 2025
Jacopo Sapienza, Marco Spangaro, Stefano Comai et al.
2 citations
Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In particular, the gene encoding complement component 4 (C4) showed the strongest association with schizophrenia, and this protein is involved in complement-dependent and microglia-mediated synaptic pruning. As a matter of fact, microglia are overactive...
Current Neurology and Neuroscience Reports
August 9, 2025
James J H Im, Claire H Sandoe
Psychedelics are often queried as a potential therapeutic option in a multitude of conditions, including pain and mental health disorders, with a growing body of patient reports and scientific publications describing potential benefit. This article reviews recent research on psychedelic compounds for treatment of headache disorders. Observational data, case reports, and a few recent small,...
Journal of Eating Disorders
July 24, 2025
Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz et al.
2 citations
There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders ("MED-FED") survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for their impact on ED symptoms and general mental...
Journal of Psychopharmacology
July 11, 2025
Diana Glenn, Seung Hee Choi, Rick S. Zimmerman
1 citation
Background: Classic serotonergic psychedelics are 5-HT2A partial agonists that induce non-ordinary states of consciousness. Many have demonstrated anti-addictive properties; however, their impact on smoking behaviors remains under-researched. This review provides a synthesis of the therapeutic potential of these compounds in promoting smoking cessation and reduction. Methods: A systematic...